Jung Han Yoon1, Min Kim2, So Young Moon2, Seok Woo Yong2, Ji Man Hong2. 1. Department of Neurology, Ajou University School of Medicine, Suwon, South Korea. Electronic address: jhyoon@gmail.com. 2. Department of Neurology, Ajou University School of Medicine, Suwon, South Korea.
Abstract
BACKGROUND: Mild cognitive impairment (MCI) is a well-known precursor of Alzheimer's disease (AD) but often also precedes dementia with Lewy bodies (DLB). The early differentiation of DLB from AD is important to delay disease progression. Olfactory dysfunction is a well-known early sign of both AD and Lewy body disorders, including Parkinson's disease (PD) and DLB. Thus, the aim of the present study was to determine whether olfactory and neuropsychological tests can aid in the differentiation of DLB from AD at the MCI stage. METHODS: The present study included 122 MCI patients who were monitored until they developed dementia or until their condition stabilized; the follow-up period averaged 4.9 years (range: 3.9-6.2 years). Baseline olfactory function as measured with the Cross-Cultural Smell Identification (CCSI) test and neuropsychological data were compared. RESULTS: During the follow-up period, 32 subjects developed probable AD (MCI-AD), 18 had probable DLB (MCI-DLB), 45 did not convert to dementia (MCI-stable), and eight developed a non-AD/DLB dementia. The mean CCSI score (95% confidence interval [CI]) in patients with MCI-DLB (4.6; 95% CI: 4.0-5.3) was significantly lower than that of MCI-AD patients (6.4; 95% CI: 6.0-6.7, p<0.001) and MCI-stable patients (7.3; 95% CI: 6.9-7.8, p<0.001). The area under the curve of the receiver operating characteristic to discriminate MCI-DLB from MCI-AD using CCSI scores was (0.84; 95% CI: 0.72-0.97). Frontal-executive function and visuospatial ability was worse in patients with MCI-DLB, while verbal recognition memory impairment was greater in those with MCI-AD. CONCLUSION: Olfactory and neuropsychological tests can help predict conversion to DLB or AD in patients with MCI.
BACKGROUND: Mild cognitive impairment (MCI) is a well-known precursor of Alzheimer's disease (AD) but often also precedes dementia with Lewy bodies (DLB). The early differentiation of DLB from AD is important to delay disease progression. Olfactory dysfunction is a well-known early sign of both AD and Lewy body disorders, including Parkinson's disease (PD) and DLB. Thus, the aim of the present study was to determine whether olfactory and neuropsychological tests can aid in the differentiation of DLB from AD at the MCI stage. METHODS: The present study included 122 MCI patients who were monitored until they developed dementia or until their condition stabilized; the follow-up period averaged 4.9 years (range: 3.9-6.2 years). Baseline olfactory function as measured with the Cross-Cultural Smell Identification (CCSI) test and neuropsychological data were compared. RESULTS: During the follow-up period, 32 subjects developed probable AD (MCI-AD), 18 had probable DLB (MCI-DLB), 45 did not convert to dementia (MCI-stable), and eight developed a non-AD/DLB dementia. The mean CCSI score (95% confidence interval [CI]) in patients with MCI-DLB (4.6; 95% CI: 4.0-5.3) was significantly lower than that of MCI-ADpatients (6.4; 95% CI: 6.0-6.7, p<0.001) and MCI-stable patients (7.3; 95% CI: 6.9-7.8, p<0.001). The area under the curve of the receiver operating characteristic to discriminate MCI-DLB from MCI-AD using CCSI scores was (0.84; 95% CI: 0.72-0.97). Frontal-executive function and visuospatial ability was worse in patients with MCI-DLB, while verbal recognition memory impairment was greater in those with MCI-AD. CONCLUSION: Olfactory and neuropsychological tests can help predict conversion to DLB or AD in patients with MCI.
Authors: Michael L Alosco; Johnny Jarnagin; Yorghos Tripodis; Michael Platt; Brett Martin; Christine E Chaisson; Christine M Baugh; Nathan G Fritts; Robert C Cantu; Robert A Stern Journal: J Neurotrauma Date: 2016-08-11 Impact factor: 5.269
Authors: David R Roalf; Madelyn J Moberg; Bruce I Turetsky; Laura Brennan; Sushila Kabadi; David A Wolk; Paul J Moberg Journal: J Neurol Neurosurg Psychiatry Date: 2016-12-30 Impact factor: 10.154
Authors: L Bonanni; A Cagnin; F Agosta; C Babiloni; B Borroni; M Bozzali; A C Bruni; M Filippi; D Galimberti; R Monastero; C Muscio; L Parnetti; D Perani; L Serra; V Silani; P Tiraboschi; A Padovani Journal: Neurol Sci Date: 2016-09-13 Impact factor: 3.307
Authors: Davangere P Devanand; Seonjoo Lee; Jose A Luchsinger; Howard Andrews; Terry Goldberg; Edward D Huey; Nicole Schupf; Jennifer Manly; Yaakov Stern; William C Kreisl; Richard Mayeux Journal: Alzheimers Dement Date: 2020-01-04 Impact factor: 21.566